Altria Abandons Option to Buy Additional Cronos Shares.

Dec.20.2022
Altria Abandons Option to Buy Additional Cronos Shares.
Altria Group cancels option to buy additional shares in Cronos Group, resulting in a $483 million capital loss.

According to a press release from Altria, the company has notified Cronos Group that it has irrevocably relinquished its options to purchase additional common shares of Cronos, as well as any ownership rights or common shares underlying those options, without any consideration.


In March 2019, Altria, through its subsidiary, acquired a 45% stake and stock warrants in Cronos. The warrants can be exercised before March 8, 2023, at a price of CAD 19 (USD 13.93) per share. Prior to abandoning the warrants, Altria's subsidiary held 156,573,537 common shares of Cronos (approximately 41% of the issued and outstanding common shares), and through full exercise of the warrants, could increase its ownership to 240,816,760 common shares of Cronos (approximately 52% of the issued and outstanding common shares after full exercise of the warrants).


On December 15th, 2022, the closing price for Cronos common shares was $3.81 CAD ($2.79 USD), and for the past 12 months, the trading price for Cronos common shares has not exceeded $6 CAD ($4.39 USD). Considering Cronos' trading level and the expiration of its warrants in March 2023, on December 16th, 2022, Altria decided to forfeit its warrants. As a result of forfeiting the warrants, Altria expects to claim a capital loss of $483 million USD in its 2022 federal merger asset tax return. Altria will continue to hold 156,573,537 shares of Cronos common stock.


Tobacco company Altria holds common stock in Cronos through its subsidiary for investment purposes. Altria will continue to assess Cronos' business and prospects, as well as all other relevant factors, to determine whether it or its affiliates will dispose of such shares on the open market through private negotiation transactions (possibly involving Cronos or third parties) or through other means.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
A UK bill banning the legal sale of tobacco to people born on or after January 1, 2009 has completed its passage through parliament. Under the bill, those born in that group will never be able to be legally sold tobacco anywhere in the UK. The legislation is expected to receive royal assent next week. It also gives ministers powers to strengthen public-place smoking restrictions and restricts branding, promotion and advertising of vape and nicotine products aimed at children.
Apr.22 by 2FIRSTS.ai
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Alexander Tolmachev, deputy chairman of the Russian State Duma Committee on Youth Policy, said the issue of licensing vape circulation will be resolved at the legislative level in the coming months. He said a significant share of such products currently on the market are counterfeit, that their real nicotine concentration may be several times higher than stated, and that the composition of the liquid is unknown.
Mar.18 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
European Commission Publishes Tobacco Control Framework Evaluation, Says Smoking and Tobacco-Related Deaths Have Declined
The European Commission has published its evaluation of the EU tobacco control framework, assessing the effectiveness, efficiency and relevance of the Tobacco Products Directive and Tobacco Advertising Directive in protecting public health and ensuring the smooth functioning of the internal market.
Apr.03 by 2FIRSTS.ai
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria will introduce new sales rules for nicotine products from April 1, 2026. Under a reform of the tobacco law passed in December 2025, nicotine pouches will in future be sold only through tobacco shops, while e-liquids will be sold only through tobacco shops and licensed specialist stores. Other points of sale will no longer be permitted to sell these products.
Mar.30 by 2FIRSTS.ai
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center said it will apply the same regulations used for conventional tobacco products to all tobacco products, including liquid e-cigarettes, from April 24, while also strengthening public guidance and smoke-free zone management.
Apr.21 by 2FIRSTS.ai